The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...

The global elastography imaging market is experiencing significant growth, with projections indicating that the industry will ...

Portal vein thrombosis (PVT) is a challenging complication in liver cirrhosis, with no currently available sensitive diagnostic markers.

Understanding the symptoms of cirrhosis can facilitate early diagnosis and intervention, improving outcomes for those ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

the researchers sought to develop a better risk score for those patients who do not have viral hepatitis or cirrhosis. In the ...

Background and Aims: Neuropathy in association with chronic liver disease, including cirrhosis, is recognized; however, there are differences in the incidence and type of neuropathy reported.

Apr. 15, 2024 — Innovative carbon beads reduce bad bacteria and inflammation in animal models, which are linked to liver cirrhosis and other serious health ... Mechanism of Action of the ...

Purpose Published evidence on the incidence and predictors of venous thromboembolism (VTE) in patients with cirrhosis of the liver is reviewed. Summary The frequently observed phenomenon of ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.